Daniel R. Jeske1,2, Jenifer A. Linehan3,4, Timothy G. Wilson3,4, Mark H. Kawachi3, Kristina Wittig3, Katarzya Lamparska3, Camille Amparo3, Rosa Mejia3, Fang Lai5, Dimitra Georganopoulou5, Steven S. Smith3
Canadian Journal of Urology, Vol.24, No.6, pp. 9089-9097, 2017
Abstract Introduction: Early biochemical recurrence after prostate cancer surgery is associated with higher risk of aggressive disease and cancer specific death. Many new tests are being developed that will predict the presence of indicators of aggressive disease like early biochemical recurrence. Since recurrence occurs in less than 10% of patients treated for prostate cancer, validation of such tests will require expensive testing on large patient groups. Moreover, clinical application of the validated test requires that each new patient be tested. In this report we introduce a two-stage classifier system that minimizes the number of patients that must… More >